Apollo Hospitals Enterprise Ltd on Friday said it will acquire International Finance Corporation’s (IFC) 31% stake in its subsidiary Apollo Health and Lifestyle Ltd (AHLL).
Post-acquisition, AHLL will become a 100% subsidiary of AHEL, with 99.42% held by Apollo and the remainder under an ESOP pool.
"The move is expected to unlock operational synergies, improve return on capital employed (ROCE), and enable disciplined growth across AHLL’s four verticals," Apollo said in a statement.
“This acquisition is a decisive step that will allow for sharper capital allocation and a greater focus on select high-potential segments,” said Suneeta Reddy, Managing Director, Apollo Hospitals. “We see AHLL becoming a value-accretive driver in Apollo’s integrated healthcare portfolio.”
AHLL consists primary care and diagnostics, birthing & women’s Health (Apollo Cradle), ambulatory care centers, dialysis & dental networks. IFC has invested in AHLL in December 2016, acquiring a 29.03% stake for Rs 450 crore. The investment was split equally between IFC’s own account and the IFC Emerging Asia Fund, managed by IFC Asset Management Company.
AHLL reported a turnover of Rs 1553.5 crore in FY25, up from Rs 1365.3 crore in FY24. The company is targeting high-teen CAGR growth in diagnostics and primary care, driven by genomics, molecular diagnostics, and personalized health screens.
“By bringing AHLL fully into Apollo’s fold, we are sharpening the business focus across its four verticals,” said Sangita Reddy, Joint Managing Director. “This sharper focus will enable AHLL to scale more effectively, innovate faster, and serve patients with care models that are more personalized, accessible, and future-ready.”
Rs 573 crore oncology investment in Gurugram
Apollo also announced plans to invest Rs 573 crore from internal accruals to set up a 100-bed Comprehensive Oncology Centre in Gurugram, featuring the Proteus One single gantry Proton Beam Therapy system. This will be Apollo’s third proton therapy installation in India, following Chennai and Hyderabad.
The Gurugram center will be part of the Phase 2 expansion of Apollo’s upcoming 500-bed hospital in the city, with completion targeted by FY29.
“The addition of next-generation proton therapy to our Apollo Proton Cancer Centres further solidifies our position as a global leader in Proton Therapy,” said Dr. Prathap C Reddy, Founder-Chairman of Apollo Hospitals.
Apollo aims to double its oncology business to over Rs 5,000 crore in the next 3-4 years, leveraging high-end personalized care, robotics, immunotherapy, genomics-driven medicine, and CAR-T cell therapies.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
